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Chronic kidney disease in pregnancy
David Williams,1 John Davison2
Pregnant women with chronic renal disease
adapt poorly to a gestational increase in
renal blood flow. This may accelerate their
decline in renal function and lead to a poor
pregnancy outcome
Chronic kidney disease is often clinically and bio-
chemically silent until renal impairment is advanced.
Symptoms are unusual until the glomerular filtration
rate declines to <25%of normal, andmore than 50%of
renal function can be lost before serum creatinine rises
above 120μmol/l.Womenwhobecomepregnantwith
serum creatinine values above 124 μmol/l have an
increased risk of accelerated decline in renal function
andpooroutcomeofpregnancy (seeScenariobox).1-4w1
Several factors must be considered when managing
pregnant women with chronic kidney disease to
minimise the adverse effects of pregnancy onmaternal
renal function and the consequent effects on the fetus.
How common is chronic kidney disease in pregnancy?
Chronic kidney disease is now widely classified into
five stages according to the level of renal function
(table 1).w2 Stages 1 and 2 (normal or mild renal
impairment with persistent albuminuria) affect up to
3% of women of child bearing age (20-39 years).w3
Stages 3-5 (glomerular filtration rate <60 ml/min)
affect around one in 150 women of childbearing age,w3
but because of reduced fertility and an increased rate of
early miscarriage, pregnancy in these women is less
common. Studies of chronic kidney disease in preg-
nancy have mostly classified women on the basis of
serum creatinine values, but we estimate that around
one in 750 pregnancies is complicated by stages 3-5.w4
Somewomen are found to have chronic kidney disease
for the first time during pregnancy. Around 20% of
women who develop early pre-eclampsia (≤30 weeks’
gestation), especially those with heavy proteinuria,
have previously unrecognised chronic kidney
disease.w5
How do physiological changes of pregnancy affect the
kidney?
The kidneys undergo pronounced haemodynamic,
renal tubular, and endocrine changes during preg-
nancy (figure; table 2). 5w6 During healthy pregnancy
the kidney increases production of erythropoietin,
active vitamin D, and renin.6
From early pregnancy, increased renal blood flow
leads to an increase in glomerular filtration rate ofmore
than 50% (figure).Gestational hyperfiltration is accom-
panied by a relative decrease in concentrations of
serum creatinine and urea, so values considered
normal in the non-pregnant state may be abnormal in
pregnancy (table 2). The plethoric kidneys appear
larger on ultrasonography and—combined with renal
pelvis and ureteric dilatation—these normal changes
seen in pregnancy mimic outflow obstruction.w7 A
5-10 g/l fall in plasma albumin, a rise in serum
cholesterol, and oedema in late pregnancy can also
occur in normal pregnancy, and sometimes simulate
nephrotic syndrome.
Can diseased kidneys tolerate normal physiological
changes of pregnancy?
Women with chronic kidney disease are less able to
make the renal adaptations needed for a healthy
pregnancy. Their inability to boost renal hormones
often leads to normochromic normocytic anaemia,
reduced expansion of plasma volume, and vitamin D
deficiency.6Thegestational rise in glomerular filtration
rate is blunted in women with moderate renal
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Table 1 | Stages of chronic kidneydiseasew2
Stage Description
Estimated GFR
(ml/min/1.73 m2)
1 Kidney damage with normal
or raised GFR
≥90
2 Kidney damage with mildly low GFR 60-89
3 Moderately low GFR 30-59
4 Severely low GFR 15-29
5 Kidney failure <15 or dialysis
GFR=glomerular filtration rate.
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impairment and usually absent in those with a serum
creatinine higher than 200 µmol/l.4 7 8 If pre-eclampsia
develops, maternal renal function often deteriorates
further, but the addition of a prerenal insult that will
reduce renal blood flow, such as peripartum haemor-
rhage or regular use of a non-steroidal anti-inflamma-
tory drug, can seriously threaten maternal renal
function. In such circumstances, nephrotoxic drugs
must be avoidedandmaternal circulation restoredwith
careful fluid management, as women with pre-eclamp-
sia are prone to pulmonary oedema.
How does pregnancy affect maternal kidney function?
Mild renal impairment (stages 1-2)
Most womenwith chronic kidney diseasewho become
pregnant have mild renal dysfunction and pregnancy
does not usually affect renal prognosis (table 3).A case-
control study of 360 women with primary glomerulo-
nephritis andmild renal dysfunction (serum creatinine
<110 μmol/l), minimal proteinuria (<1 g/24 h), and
absent or well controlled hypertension before preg-
nancy showed that pregnancy had little or no adverse
effect on long term (up to 25 years) renal function in the
mother. 9 The situation is different for women with
moderate to severe renal impairment.
Moderate to severe renal impairment (stages 3-5)
Small mainly uncontrolled retrospective studies have
shown thatwomenwith theworst renal function before
pregnancy are at greatest risk of an accelerated decline
in renal function during pregnancy (table 3). Pre-
existing proteinuria and hypertension both increase
this risk. 2 4 8w17 w18 A retrospective series of womenwith
chronic kidney disease (87 pregnancies) found that
those who initially had moderate renal impairment
(serum creatinine 124-168 mmol/l) had a 40% risk of a
decline in renal function during pregnancy, which
persisted after birth in about half of those affected.3
However, 13 of 20 women with severe renal impair-
ment (serum creatinine >177 mmol/l) had a decline in
renal function during the third trimester, which
persisted in most women and deteriorated to end
stage renal failure in seven.3w1
A prospective study assessing the rate of decline of
maternal renal function during pregnancy in 49
women with chronic kidney disease stages 3-5 before
pregnancy confirmed these earlier observations.2
Women with both an estimated glomerular filtration
rate <40 ml/min/1.73 m2 and proteinuria >1 g/24 h
before pregnancy showed an accelerated decline in
renal function during pregnancy.2 Chronic hyperten-
sion predisposes women to pre-eclampsia—this may
explain why some women with milder renal dysfunc-
tion also have a gestational decline in renal function.2 3
The risk of such a decline is reduced when hyperten-
sion is controlled.
How does chronic kidney disease affect pregnancy
outcome?
Maternal hypertension, proteinuria, and recurrent
urinary tract infection often coexist in women with
chronic kidney disease, and it is difficult to tell how
Table 2 | Physiological changes in common indices of renal function during healthy pregnancy. Values aremean (SD)5 w6
Measure
Stage of pregnancy
Before pregnancy First trimester Second trimester Third trimester
Effective renal plasma flow (ml/min) 480 (72) 841 (144) 891 (279) 771 (175)
Glomerular filtration rate (ml/min)measured
by inulin clearance
105 (24) 162 (19) 174 (24) 165 (22)
Glomerular filtration rate (ml/min)measured
by 24 h creatinine clearance
98 (8) 151 (11) 154 (15) 129 (10)
Serum creatinine (μmol/l) 73 (10) 60 (8) 54 (10) 64 (9)
Plasma urea (mmol/l) 4.3 (0.8) 3.5 (0.7) 3.3 (0.8) 3.1 (0.7
Plasma urate (μmol/l) 246 (59) 189 (48) 214 (71) 269 (56)
Plasma osmolality (mosmol/kg) 290 (2) 280 (3) 279 (3) 279 (5)
Fasting cholesterol (mmol/l) 5.0 (0.3) 5.5 (0.4) 6.9 (0.4) 7.8 (0.4)
Renal haemodynamics
    Renal blood flow (70%)
    Plethoric kidney swells 
    Bipolar diameter (1cm)
    Glomerular filtration rate (50%)
    Proteinuria (< 260 mg/24 h)
Tubular function
    Glycosuria
    Bicarbonaturia (metabolic acidosis)
    Calciuria
    Plasma osmolality
      (   10 mosmol/kg)
Endocrine function
    Renin
    Erythropoietin
    Active vitamin D
    Pelvicalyceal
dimensions
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much each of these factors contributes to a poor
pregnancy outcome. It seems, however, that each
factor is individually and cumulatively detrimental to
fetal outcome.2-4 6-8w1
Women with severe renal impairment have the
greatest difficulty conceiving, the highest rate of
miscarriage, and the poorest pregnancy outcome.1-4 7 8
The degree of renal dysfunction correlateswith the risk
of a poor pregnancy outcome (table 3).
How should chronic kidney disease be managed in
pregnancy?
All women with chronic kidney disease should be
referred early in pregnancy to anobstetrician andother
specialist as necessary, to plan subsequent antenatal
care. However, with a few exceptions, the most
important aspects of managing chronic kidney disease
in pregnancy relate to managing associated clinical
features, rather than the typeof kidneydisease.Regular
monitoring of maternal renal function (serum creati-
nine and serumurea), blood pressure,midstreamurine
(for infection), proteinuria, and when appropriate
ultrasound (to detect urological obstruction) should
identify pathological changes and allow timely inter-
vention to optimise perinatal outcome and maternal
renal outcome (table 4).
Before pregnancy
Ideally, all women with chronic kidney disease should
be made aware of the risks to their long term renal
function and to the fetus before they conceive (table 3).
Women with chronic kidney disease often have
amenorrhoea but may still occasionally ovulate and
thus conceive. Contraceptive measures that consider
clinical comorbidities should be taken by thosewho do
not wish to become pregnant.
Folic acid 400 µg daily should be given as usual
before conception until 12 weeks’ gestation. Low dose
aspirin (50-150 mg/day) should be started in early
pregnancy to reduce the risk of pre-eclampsia and
improve perinatal outcome.10 Regular drugs should be
reviewed. Fetotoxic drugs—such as angiotensin con-
verting enzyme inhibitors and angiotensin II receptor
blockers—should be stopped before pregnancy if
equally effective drugs are available, or as soon as
pregnancy is confirmed, if they are thought to be
important for protecting maternal renal function.w22
During pregnancy
Chronic kidney disease includes a wide range of
different conditions, andmonitoringduringpregnancy
must be tailored to the severity of the disease and its
complications (tables 4, 5). In general, all clinical and
biochemical features should be checked more often as
pregnancy progresses or if changes suggest deteriorat-
ing kidney function. Specialist care should begin early
in pregnancy, but much of the monitoring of women
with stage 1-2 disease can be done by primary care
doctors.
When should specialists be involved?
Optimal management of pregnant women with
chronic kidney disease often involves the combined
expertise of specialists in obstetrics, nephrology,
urology, fetal medicine, and neonatology. Impressive
improvements in perinatal outcome over recent
Table 3 | Estimated effects of prepregnancy renal function on pregnancy outcome andmaternal renal function. Values are the
estimated percentage ofwomen or neonates affected
Mean (SD) prepregnancy
serum creatinine value
(µmol/l)
Effects on pregnancy outcome Loss of >25% renal function
Fetal growth
restriction
Preterm
delivery
Pre-
eclampsia
Perinatal
deaths
During
pregnancy
Persists
postpartum
End stage renal failure
after 1 year
<125 25 30 22 1 2 0 0
125-180 40 60 40 5 40 20 2
>180 65 >90 60 10 70 50 35
On dialysis >90 >90 75 50* N/A N/A N/A
N/A=not applicable.
Estimates are based on literature from 1985-2007, with all pregnancies attaining at least 24 weeks’ gestation.1-4 7 8 w8-w16
*If conceived on dialysis, 50% of infants survive; if conceived before introduction of dialysis, 75% of infants survive.
SCENARIO
A 37 year old woman with a history of reflux nephropathy and recurrent urinary tract
infections presented for prepregnancy counselling with a serum creatinine of 153 μmol/l,
hypertension controlledwith ramipril 5mgdaily, andproteinuria of 1.4 g/24h. The effect of
pregnancy on her renal function and the increased risk of complications during pregnancy
wereexplained.Shewasadvised to take folicacid400μgdailyandassoonassheknewshe
was pregnant to stop ramipril and start low dose aspirin (75 mg daily) to reduce the risk of
pre-eclampsia.
She presented again 18 months later at 10 weeks’ gestation. Her blood pressure was
144/92mmHgwithnoantihypertensives,serumcreatininewas136μmol/l,andshehadan
asymptomatic urinary tract infection with Escherichia coli. The infection was treated with
cefalexin500mgthree timesdaily for sevendays,andprophylactic cefalexin125mgnightly
wascontinued for the restof thepregnancy. Thromboprophylaxiswith lowmolecularweight
heparin (enoxaparin 40 mg daily) was started because of the prothrombotic effect of
proteinuria (>1 g/24h) andpregnancy. At 28weeks, her bloodpressurewas152/98mmHg
and shewas treated with nifedipine SR 10mg twice daily. At 29 weeks, her blood pressure
rose to 166/104 mm Hg, despite increased nifedipine SR 20 mg twice daily, and her renal
functionstarted todeteriorate (serumcreatinine188μmol/l). Pre-eclampsiawasdiagnosed
from the rise in blood pressure, raised liver transaminases (alanine transaminase 147 IU/l,
aspartate transaminase96 IU/l), and fall in platelet count (to82×109/l). Fetal growthwasat
the fifth centile and had been reviewed with ultrasound every two weeks since 24 weeks’
gestation. A caesarean section was carried out at 30+2 weeks because of signs of fetal
distress and worsening maternal pre-eclampsia and renal function (serum creatinine 209
μmol/l), and a 1.1 kg baby boy was delivered.
Six months later, maternal renal function had not recovered to prepregnancy levels
(serum creatinine 193 μmol/l). Hypertension was treated with ramipril and nifedipine SR.
The baby was doing well, although he was still small for age.
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decades have been driven by advances in all of these
specialties.2-4w1 Sonographic assessment of uterine
artery blood flow at 20-24 weeks’ gestation can refine
the risk of later pre-eclampsia and fetal growth
restriction.w32 Difficult decisions about the timing of
delivery and managing renal function in women with
kidney transplants and systemic disorders such as
systemic lupus erythematosus and other vasculitidies
require expert management.6 Urological expertise is
necessary for themanagement of obstructive disorders
involving renal stones, congenital pelvo-ureteric
abnormalities, or rare gestational obstructive
disorders.6 Maternal renal conditions with a genetic
basis sometimes require specialist fetal medicine or
genetic advice. The most common inherited renal
condition, autosomal dominant polycystic kidney
disease, is passed on to 50% of offspring.
Postpartum care
It can take up to three months, occasionally longer, for
the physiological changes of pregnancy to disappear.
During that time, close monitoring of fluid balance,
renal function, blood pressure, and a further review of
drug treatment are necessary. Women who have new
onset proteinuria associatedwith pre-eclampsia should
be followed until proteinuria disappears, or until a
diagnosis of renal disease is made.
Breast feeding should be encouraged in womenwith
chronic kidney disease. Information is confusing as to
the extent to which some immunosuppressive drugs—
such as ciclosporin and tacrolimus—appear in breast
milk,w33 but prednisolone, azathioprine, and angioten-
sin converting enzyme inhibitors are barely detectable
in breast milk. It is still unclear whether the benefits of
breast feeding are countered by neonatal absorption of
immunosuppressive drugs. We generally encourage
mothers who want to breast feed but are taking
immunosuppressive drugs to do so as long as the
baby is thriving.
Conclusions
Women with chronic kidney disease who become
pregnant usually havemild renal dysfunction (stages 1-
2) and have an uneventful pregnancy and good renal
Table 5 | Summary of important points regarding specific kidneydiseases during pregnancy
Condition Possible complications that need monitoring Key management points
Primary glomerulonephritis Hypertension; proteinuria; recurrent infection Treat associated clinical features; outcome relates to control of clinical
features and severity of renal impairment
Autosomal dominant polycystic
kidney disease
Impaired renal function; hypertension Make parents aware that the child has a 50% risk of inheriting the
conditionw23
Congenital urinary tract obstruction Increased risk of urinary tract obstruction, even if previously surgically
correctedw24
Perform kidney ultrasound in early pregnancy; serial assessment of renal
function, urine culture, and blood pressure; repeat ultrasound if
abnormalities in monitored parameters
Vesicoureteric reflux nephropathy Recurrent urinary tract infectionsw24; ureteral obstruction; pre-existing
renal impairment; hypertension
Prophylactic antibiotics may be needed; drainage of obstruction may also
be necessary
Nephrolithiasis Renal colicw25; ureteric obstruction Magnetic resonance urography can be used in diagnosis to avoid exposure
to radiationw26
Diabetic nephropathy Declining renal function in women with pre-existing diabetic
nephropathyw27; hypertension and proteinuria
Try to maintain good glycaemic control before, during, and after pregnancy
Nephritis caused by systemic lupus
erythematosus
Can present like pre-eclampsia so investigate for distinguishing clinical
and immunological featuresw28
Drug treatment managed by rheumatologist and obstetrician
Dialysis Adjust dialysis to mimic the physiological changes of pregnancyw29 Haemodialysis is more effective than peritoneal dialysis at mimicking
physiological change
Renal transplant Pre-eclampsia; fetal growth restriction; deteriorating graft functionw30 Delay pregnancy until graft function and immunosuppression are
stabilisedw31
Table 4 | Care of womenwith chronic kidneydisease during pregnancy
Measure Details of monitoring
Urine Every 4-6 weeks check for (1) infection—keep urine sterile with prophylactic antibiotics after one urinary tract
infectionw19; (2) proteinuria—use thromboprophylaxis with low molecular weight heparin if >1 g proteinuria/24 h; (3)
haematuria—if present, performmicroscopy for red cell casts, which suggest active renal parenchymal disease. Normal
red cell morphology suggests urological pathology—seek urological advice
Blood pressure Checkbloodpressure regularly, dependingonhowwell bloodpressure is controlled. Aim tokeep it between120/70mm
Hg and 140/90 mm Hg with antihypertensive treatment. Inappropriately low blood pressure is associated with fetal
growth restriction, high blood pressure is associated with renovascular damage
Renal function Check serum creatinine and urea, depending on stage of disease.* More frequently for disease stages 3-5 and in the
second half of pregnancy
Full blood count Check haemoglobin and recognise the need for iron (serum ferritin) and erythropoietin to keep haemoglobin
at 100-110 g/lw20
Ultrasound of renal tract Perform baseline renal ultrasound at booking (around 12 weeks’ gestation) for pelvicaliceal dimensions. Repeat if
symptoms suggest obstruction
*UK laboratories have been encouraged to report estimated glomerular filtration rate using the validated modification of diet in renal disease formula,
whereby serum creatinine is adjusted for age, sex, and race. In pregnancy, however, this formula significantly underestimates the rate and cannot be
recommended for use in clinical practice.w21
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outcome. Clinical features, in particular uncontrolled
hypertension, heavy proteinuria (>1 g/24 h), and
recurrent urinary tract infections have an independent
and cumulative negative effect on the outcome of
pregnancy. Women with moderate to severe disease
(stages 3-5) are at highest risk of complications during
pregnancy and of an accelerated decline in renal
function. Successful management of women with
chronic kidney disease during pregnancy requires
teamwork between primary care clinicians, midwives,
specialists, and the patient. Frequent monitoring of
simple clinical and biochemical features will guide
timely expert intervention to achieve optimal preg-
nancy outcome and conservation of maternal renal
function.
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Patients with suspected rheumatoid arthritis should be
referred early to rheumatology
Kimme L Hyrich
The clinical problem
Rheumatoid arthritis affects 1% of adults and is
associatedwith progressive joint damage and disability
and increased mortality. Treatment with disease
modifying anti-rheumatic drugs (DMARDs), such as
methotrexate, has been shown to reduce the progres-
sion of radiologically evident joint damage and
improve long term disability. A shift towards starting
DMARD treatment as early as possible has therefore
occurred. Guidelines recommend that patients should
be referredearly, ideallywithin sixweeksof theonsetof
symptoms,1 and that DMARDs should be started
within 12 weeks of onset.2 However, a recent survey
found that only 50% of patients were assessed by a
rheumatologist within this time.3 I propose that
patients with suspected rheumatoid arthritis should
be referred to rheumatology as soon after first
presentation as possible.
Evidence for change
Benefits of early treatment:
A recent meta-analysis of 12 studies (six open label
extensions of randomised controlled trials and six
observational cohort studies) examined the association
between delay to DMARD treatment and radiological
progression in patients with early rheumatoid arthritis
(<2 years at presentation).4 The average time between
early and delayed treatment was nine months. After a
median of three years of observation, patients who
received early treatment had33% less progression than
delayed patients.
A secondmeta-analysis of 14 randomised controlled
trials of DMARD treatment in rheumatoid arthritis
found that the strongest predictor of improvements in
disease activity (according to the American College of
Rheumatology definition5) was shorter disease dura-
tion at start of treatment. The best response was in
patients treated within a year of symptom onset.6
The very recent PROMPT trial compared metho-
trexate and placebo in 110 patients with undifferen-
tiated polyarthritis (not yet fulfilling criteria for
established rheumatoid arthritis).7 8 The median dis-
ease duration was nine months. The trial concluded
that treatment with methotrexate delayed the onset of
Change Page aims to alert
clinicians to the immediate need
for a change in practice to make it
consistent with current evidence.
The change must be
implementable and must offer
therapeutic or diagnostic
advantage for a reasonably
common clinical problem.
Compelling and robust evidence
must underpin the proposal for
change.
Methods
I searchedMedline (1950 toMay2007)with the following
MeSH headings: “rheumatoid arthritis”, “antirheumatic
agents”, and “treatment outcome”, as well as the key
words “early” and “delay”. In addition, I reviewed
bibliographies of identified papers and recent treatment
guidelines.
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